KAMADA LTD (KMDA) Stock Price, Quote, News and Overview
NASDAQ:KMDA - Nasdaq - IL0010941198 - Common Stock - Currency: USD
KMDA Quote, Performance and Key Statistics
KAMADA LTD
NASDAQ:KMDA (1/23/2025, 12:47:25 PM)
7.26
-0.27 (-3.59%)
The current stock price of KMDA is 7.26 USD. In the past month the price increased by 28.72%. In the past year, price increased by 31.18%.
KMDA Latest News, Press Releases and Analysis
Kamada Announces a $25 Million 3-Year Contract for Supply of KAMRAB® and VARIZIG® in Latin America
REHOVOT, Israel and HOBOKEN, N.J., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a...
Kamada Affirms 2024 Financial Guidance and Announces Expected Continued Double-Digit Profitable Growth for 2025
• Provides 2025 Annual Guidance of $178 - $182 Million in Revenue and $38 - $42 Million of Adjusted EBITDA, Representing Year-Over-Year Increase of 13% in...
Kamada Reports Continued Profitable Growth with Strong Third Quarter and Nine Month 2024 Financial Results; Raises Full-Year Profitability Guidance
Revenues for Third Quarter of 2024 were $41.7 Million, up 10% Year-over-Year; Nine Month 2024 Total Revenues were $121.9 Million, up 15%...
Kamada Announces Expansion of Plasma Collection Operations in Texas with the Opening of New Site in Houston
New Plasma Collection Center in Houston Now Open, with Planned Annual Collection Capacity of Approximately 50,000 Liters and an Estimated Annual Revenue...
KMDA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.81 | 300.41B | ||
| AMGN | AMGEN INC | 14.31 | 147.86B | ||
| GILD | GILEAD SCIENCES INC | 20.94 | 115.60B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 851.38 | 111.82B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.1 | 75.41B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.71B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.07B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.88B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.42B | ||
| NTRA | NATERA INC | N/A | 22.60B | ||
| BIIB | BIOGEN INC | 8.74 | 20.79B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.41B |
Related screens
About KMDA
Company Profile
Kamada Ltd. is a biopharmaceutical company, which focuses on specialty plasma-derived therapeutic. The firm uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
Company Info
KAMADA LTD
2 Holtzman St., Science Park
Rehovot 7670402 IL
CEO: Amir London
Employees: 378
Company Website: https://www.kamada.com/
Investor Relations: https://www.kamada.com/contact_topics/investor-relations-2
Phone: 97289406472
KMDA FAQ
What is the price of KMDA?
The current price of KMDA is 7.26 USD.
What is the symbol for KAMADA LTD?
The exchange symbol of KAMADA LTD is KMDA and it is listed on the Nasdaq exchange.
On which exchange is KMDA listed?
KMDA is listed on the Nasdaq exchange.
Is KMDA a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for KMDA, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of KMDA.
Does KMDA pay dividends?
KMDA does not pay a dividend.
When does KMDA report earnings?
KMDA will report earnings on 2025-02-12, after the market close.
What is the Price/Earnings (PE) ratio of KMDA?
The PE ratio for KMDA is 25.93. This is based on the reported non-GAAP earnings per share of 0.28 and the current share price of 7.26 USD.
What is the Short Interest ratio of KMDA?
The outstanding short interest for KMDA is 0.07% of its float.
KMDA Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to KMDA. When comparing the yearly performance of all stocks, KMDA is one of the better performing stocks in the market, outperforming 88.96% of all stocks.
KMDA Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to KMDA. KMDA is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.
KMDA Financial Highlights
Over the last trailing twelve months KMDA reported a non-GAAP Earnings per Share(EPS) of 0.28. The EPS increased by 115.38% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 9.92% | ||
| ROA | 4.47% | ||
| ROE | 6.16% | ||
| Debt/Equity | 0.04 |
KMDA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to KMDA. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of 60.94% and a revenue growth 12.52% for KMDA